21 October 2024
Incyte Announces Health Canada Approval of OPZELURA® (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) and Nonsegmental Vitiligo
News provided by Incyte Biosciences Canada - First and only…